SharmilaMakhijaMDMBA

PubMed

• Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
  Sharmila Makhija, Lukas C. Amler, Dana Glenn, Frederick R. Ueland, Michael A. Gold, Don S. Dizon, Virginia E. Paton, Chin-Yu Lin, Thomas Januario, Kimmie Ng, Andreas S...> ;Journal of Clinical Oncology. 2010 Mar 1
• HER pathway gene expression analysis in a phase II study of pertuzumab + gemcitabine vs. gemcitabine + placebo in patients with platinum-resistant epithelial ovarian c...
  Amler L, Makhija S, Januario T, Matulonis UA, Strauss A, Dizon DS, Sliwkowski MX, Dolezal M, Tong B, Paton V> ;J. Clin. Oncol.. 2008-05-20
• Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-Δ24-RGD, in anticipation of a phase I trial for recurrent ovar...
  John G. Page, Baohong Tian, Karen Schweikart, Joseph E. Tomaszewski, Raymond D. Harris, Trevor Broadt, Judith Polley-Nelson, Patricia E. Noker, Minghui Wang, Sharmila ...> ;American Journal of Obstetrics and Gynecology. 2007 Apr 1
• Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma
  Zeng Bian Zhu, Yabing Chen, Sharmila K. Makhija, Baogen Lu, Minghui Wang, Angel A. Rivera, Masato Yamamoto, Shuyi Wang, Gene P. Siegal, David T. Curiel, Jay M. McDonald> ;International Journal of Oncology. 2006 Nov 1
• A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum-resistant ovarian cancer (OC): Preliminary safety data.
  Glenn D, Ueland F, Bicher A, Dizon D, Gold M, Makhija S, Fleming GF, Matulonis U, McGuire WP, Lieberman G> ;J. Clin. Oncol.. 2006-06-20
• Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo
  Zeng B. Zhu, Sharmila K. Makhija, Baogen Lu, Minghui Wang, Angel A. Rivera, SangAe Kim-Park, Ilya V. Ulasov, Fen Zhou, Ronald D. Alvarez, Gene P. Siegal, David T. Curiel> ;International Journal of Oncology. 2005 Jul 1
• Transcriptional targeting of tumors with a novel tumor-specific survivin promoter.
  Zeng B. Zhu, Sharmila K. Makhija, Baogen Lu, Minghui Wang, Lioudmila Kaliberova, Bin Liu, Angel A. Rivera, Dirk M. Nettelbeck, Parameshwar J. Mahasreshti, Charles A. L...> ;Cancer Gene Therapy. 2004 Apr 1
• Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter
  Z. B. Zhu, Sharmila K. Makhija, Baogen Lu, M. Wang, Lyudmila N. Kaliberova, Bin Liu, Angel A. Rivera, Dirk M. Nettelbeck, Parameshwar J. Mahasreshti, Charles A. Leath,...> ;Gene Therapy. 2004 Apr 1
• Positron Emission Tomography/Computed Tomography Imaging for the Detection of Recurrent Ovarian and Fallopian Tube Carcinoma: A Retrospective Review
  Sharmila K. Makhija, N. Howden, R. Edwards, John M. Kelley, David W. Townsend, C.C. Meltzer> ;Gynecologic Oncology. 2002 Apr 1
• Complications associated with intraperitoneal chemotherapy catheters.
  Sharmila K. Makhija, M. Leitao, Paul Sabbatini, N. Bellin, Lois Almadrones, Larry Leon, D. R. Spriggs, Richard R. Barakat> ;Gynecologic Oncology. 2001 Apr 1
• Intraperitoneal Cisplatin and Intravenous Paclitaxel in the Treatment of Epithelial Ovarian Cancer Patients with a Positive Second Look
  Sharmila K. Makhija, Paul Sabbatini, Carol Aghajanian, Ennapadam Venkatraman, D. R. Spriggs, Richard R. Barakat> ;Gynecologic Oncology. 2000 Oct 1
• Intraperitoneal chemotherapy strategies in the treatment of epithelial ovarian carcinoma.
  Sharmila K. Makhija, Paul Sabbatini, Richard R. Barakat> ;Current Opinion in Obstetrics & Gynecology. 1999 Feb 1
• Ovarian cancer staging: time for a closer look?
  Spriggs DR, Makhija S> ;J. Clin. Oncol.. 1998-08-01
• Join now to see all